ATR 101

Drug Profile

ATR 101

Alternative Names: ATR-101

Latest Information Update: 10 Mar 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator University of Michigan
  • Developer Millendo Therapeutics
  • Class Antineoplastics
  • Mechanism of Action Acetyl CoA C-acetyltransferase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Adrenocortical carcinoma
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Congenital adrenal hyperplasia; Cushing syndrome
  • Phase I Adrenocortical carcinoma

Most Recent Events

  • 20 Feb 2017 Millendo Therapeutics plans a phase II trial for Cushing's syndrome in USA (NCT03053271)
  • 01 Feb 2017 Phase-II clinical trials in Cushing's syndrome in USA (PO) (NCT03053271)
  • 02 Nov 2016 Interim adverse events data from a preclinical study in Adenocorticol carcinoma released by Millendo Therapeutics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top